Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer

NCT07702305 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

15

Enrollment

OTHER_GOV

Sponsor class

Conditions

EGFR-TKI-resistant Non-small Cell Lung Cancer With Leptomeningeal Metastasis

Interventions

DRUG: Sacituzumab tirumotecan

Sponsor

Henan Cancer Hospital